Branch Retinal Vein Occlusion

Evaluation and management of branch retinal vein occlusion.

What is a Branch Retinal Vein Occlusion?

A branch retinal vein occlusion occurs when, because of hardening of the arteries, a branch retinal artery compresses a branch retinal vein causing blockage of the vein and decreased circulation in the distribution of that branch retinal vein. (see image) [note: the branch arteries are really arteriols and the branch veins are really veinules] There are several possible treatments for branch retinal vein occlusion including intravitreal injections, laser, and even surgery. Patients with BRVO lose vision for several reasons: poor circulation, hemorrhage and macular edema (swelling). There is no treatment, at the moment, to increase circulation or to remove hemorrhage. The macular edema, however, does respond well to intravitreal injections with Lucentis, Avastin, or steroids.

Read more

Lucentis for Branch Retinal Vein Occlusion

Monthly Lucentis therapy is also helpful in improving vision in patients with branch retinal vein occlusion and macular edema. Without treatment about 30 percent of have visual improvement. With treatment about 60 percent of patients have improved vision. Long term follow-up show that at 4 years, about half of the patients with branch retinal vein occlusion require continued treatment to maintain the visual benefit.


Eylea for Branch Retinal Vein Occlusion

Eylea was approved for treatment of branch retinal vein occlusion in late 2014. It is administered as an intravitreal injection monthly initially and then the treatment interval can be extended.


Branch Retinal Vein Occlusion NEWS

Below are current articles from a Google News Feed on Branch Retinal Vein Occlusion

Vitrectomy for macular edema due to retinal vein occlusion | OPTH  Dove Medical Press

Kazuyuki Kumagai,1 Nobuchika Ogino,2 Marie Fukami,1 Mariko Furukawa1 1Kami-iida Daiichi General Hospital, Aichi, Japan; 2Shinjo Ophthalmologic Institute, ...

Grading of macular perfusion in retinal vein occlusion using en-face swept-source optical coherence tomography angiography: A retrospective observational case series  MD Linx

Researchers conducted this retrospective observational case series to assess the effectiveness of swept –source optical coherence tomography angiography ...

The Value of Retinal Vein Occlusion Therapeutics Market Estimated to Soar Higher During 2015 – 2021  PortNews24

Retinal vein occlusion (RVO) is one of the major cause of visual loss among the geriatric population. RVO is the second common cause of blindness after ...

Regeneron Pharmaceuticals, Inc. - Consenus Indicates Potential 27.5% Upside  DirectorsTalk Interviews

Regeneron Pharmaceuticals, Inc. found using ticker (REGN) have now 21 analysts covering the stock with the consensus suggesting a rating of 'Buy'. The.

Bilateral central retinal vein occlusion as the first manifestation in chronic myeloid leukaemia  The BMJ

BMJ 2019; 364 doi: https://doi.org/10.1136/bmj.l685 (Published 21 February 2019) Cite this as: BMJ 2019;364:l685. Article; Related *content*; Metrics; Responses ...

Retinal Vein Occlusion Therapeutics Market: Industry Analysis, Size, Share, Growth, Trends, And Forecasts 2019–2024  Burbank Observer

Retinal Vein Occlusion Therapeutics Market report on title “Global Retinal Vein Occlusion Therapeutics Market 2018 by Manufacturers, Countries, Type and ...

Protective effects of ADM-RAMP2 system make it a new therapeutic target for retinal vein occlusion  Medical Xpress

A clot in the retinal vein can lead to severe and irreversible loss of vision. In a report in the American Journal of Pathology investigators utilize a newly developed ...

Retinal Vein Occlusion Market Rising Demand Seen in Healthcare at a CAGR of 11.2% by 2023 | By Types Branch Retinal Artery Occlusion, Central Retinal Vein Occlusion – Says MRFR |  Medgadget

Market Research Future published a research report on “Global Retinal Vein Occlusion Market” to track and analyses developments which are competitive in.

Researchers confirm link between retinal vein occlusion, heart attack  Cardiovascular Business

In a large, retrospective study of the Taiwan population, researchers found individuals with retinal vein occlusion (RVO) demonstrated an adjusted risk increase ...

Anti-VEGF treatment of macular edema associated with retinal vein occl | OPTH  Dove Medical Press

Anti-VEGF treatment of macular edema associated with retinal vein occlusion: patterns of use and effectiveness in clinical practice (ECHO study report 2) J ...

Ozurdex for retinal vein occlusion approved in China  Healio

The Chinese Food and Drug Administration has approved Ozurdex to treat adults with macular edema after branch retinal vein occlusion or central retinal vein ...

Eylea Market Share 2x more Than Lucentis in WMD and 3x more in DME/DR based on Medicare Claims Analysis  Dexur

Dexur's analysis of medicare claims shows that Eylea (Aflibercept) is being used twice as much as Lucentis (Ranibizumab) for Wet Age-related Macular ...

Retinal Vein Occlusion Therapeutics Market Size: Technological Advancement & Growth Analysis with Forecast to 2025 - Press Release  Digital Journal

The Retinal Vein Occlusion Therapeutics market report includes a comprehensive analysis of the competitive landscape of this vertical.- The report provides an ...

Fmr LLC Sells 924,371 Shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN)  Rockland Register

Fmr LLC decreased its position in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 17.3% in the 1st quarter, according to its most recent Form 13F filing ...

Retinal Vein Occlusion Therapeutics Market 2019: Development Study by Global Industry Summary, Revenue, Gross Margin and Market Segment by 2024  The Port Bulletin

“Retinal Vein Occlusion Therapeutics Market Analysis, Development and Forecast 2019 – 2024” providing significant insights and providing a competitive ...

Young scientist helps identify cause of widespread eye disease  Science Daily

Branch retinal vein occlusion -- blockage of the blood vessels that channel blood from the retina -- is a common eye disease. A type of blood clot in the eye, the ...

Intravitreal Diclofenac in the Treatment of Macular Edema Due to Branch Retinal Vein Occlusion  Healio

Ophthalmic Surgery, Lasers and Imaging Retina | BACKGROUND AND OBJECTIVE: To evaluate the effect of a single dose of intravitreal diclofenac on macular ...

Regeneron Pharmaceuticals (NASDAQ:REGN) Downgraded to “Sell” at ValuEngine  Tech Know Bits

Regeneron Pharmaceuticals (NASDAQ:REGN) was downgraded by ValuEngine from a “hold” rating to a “sell” rating in a research report issued to clients and ...

IOP spikes more likely after treatment in certain patients  Healio

Mild to moderate IOP spikes were seen after multiple injections of Ozurdex for treatment of uveitis, diabetic macular edema and retinal vein occlusion, but ...

Global Placenta Growth Factor Market Outlook 2019 – 2025 : Alteogen Inc., Chengdu Kanghong Pharmaceuticals Group Co Ltd, Clearside BioMedical – PortNews24  PortNews24

Global Placenta Growth Factor Market research report offers high-quality insights and in-depth information of Placenta Growth Factor Industry. It provides vital ...

Intravitreal corticosteroid implant vs intravitreal ranibizumab for th | DDDT  Dove Medical Press

Intravitreal corticosteroid implant vs intravitreal ranibizumab for the treatment of macular edema: a meta-analysis of randomized controlled trials Qingquan Wei,1 ...

Driving licence - Medical conditions you need to tell the DVLA about to avoid £1,000 fine  Express

MOTORISTS must tell DVLA about different medical conditions on their driving licence to avoid landing a fine.

Retinal Vein Occlusion Market Report 2019 Top Companies, Sales, Revenue, Forecast and Detailed Analysis  Rochester Leader

This research by 360 Research Reports covers the current market size of the Retinal Vein Occlusion along with the growth rate over the years. In addition to this, ...

FDA OKs Aflibercept (Eylea) for All Retinal Vein Occlusions  Medscape

The US Food and Drug Administration (FDA) has expanded the indication of aflibercept (Eylea, Regeneron) injection to include all forms of macular edema after ...

Placenta Growth Factor Market Report Size 2019, Global Trends, Industry Share, Growth Drivers, Business Opportunities and Demand Forecast to 2023  Thе Lоuіsvіllе Rеpоrts

The Global Placenta Growth Factor Market research report reveals factual and expansive evaluation of global Placenta Growth Factor industry considering ...

Allergan's eye implant recalled due to foreign substance  Korea Biomedical Review

Allergan is recalling Ozurdex Intravitreal Implant 700㎍ (ingredient: dexamethasone), a steroid eye implant for macular edema, after detecting a foreign ...

RELATE study: Increased ranibizumab, laser yield minimal benefits  Healio

BOSTON — An increased dose of ranibizumab offered no added benefit in eyes with retinal vein occlusion, according to a study presented here. Additionally ...

Should We WAVE Goodbye to Laser?  Medscape

This study helps answer a common clinical question as to whether peripheral laser to areas of retinal ischemia improves vision and reduces injection burden in ...

Complications After Intravitreal Injection Aggravate  Medscape

VANCOUVER, Canada — Clusters of inflammatory responses after intravitreal injections have unnerved some specialists, who will share their experiences and ...

Retinal Vein Occlusion Market Clinical Research Analysis 2019 to 2025  Market Research Periodical

The report presents an in-depth assessment of the Retinal Vein Occlusion including enabling technologies, key trends, market drivers, challenges, ...

Ozurdex® (dexamethasone 0.7mg) now available for millions of patients in China with macular edema secondary to retinal vein occlusion  Markets Insider

--An estimated 7.4 million people in China are living with this sight-threatening conditioni,ii,iii --. DUBLIN, March 22, 2018 /PRNewswire/ -- Today, Allergan plc ...

Asia-Pacific Placenta Growth Factor Market Report 2018  Market Research Gazette

In this report, the Asia-Pacific Placenta Growth Factor market is valued at USD XX million in 2017 and is expected to reach USD XX million by the end of 2025, ...

NICE backs Bayer's Eylea as first-line BRVO treatment  PMLiVE

Bayer's Eylea (aflibercept) has been recommended for use on the NHS in England and Wales as a first-line treatment for adults with branch retinal vein ...

FDA to Review EYLEA (aflibercept) Injection for the Treatment of Diabetic Retinopathy  PR Newswire

TARRYTOWN, N.Y., Sept. 13, 2018 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug ...

Retinal artery and vein thrombotic occlusion during pregnancy: markers | OPTH  Dove Medical Press

Retinal artery and vein thrombotic occlusion during pregnancy: markers for familial thrombophilia and adverse pregnancy outcomes Will S Kurtz,1 Charles J ...

Regeneron (REGN) to Report Q1 Earnings: What's in Store?  Yahoo Finance

Regeneron Pharmaceuticals, Inc. REGN is scheduled to release first-quarter 2019 results on May 7, before the opening bell. In the last reported quarter, the ...

Regeneron Pharmaceuticals (NASDAQ:REGN) Upgraded to “Hold” at ValuEngine  Rockland Register

Regeneron Pharmaceuticals (NASDAQ:REGN) was upgraded by research analysts at ValuEngine from a “sell” rating to a “hold” rating in a report released on ...

United States Placenta Growth Factor Market Report 2018  Market Mirror

In this report, the United States Placenta Growth Factor market is valued at USD XX million in 2017 and is expected to reach USD XX million by the end of 2025, ...

Bayer files eye drug Eylea for new use in EU  PMLiVE

Bayer has filed an application to extend the indications of its ophthalmic drug Eylea in Europe to include use in patients with branch retinal vein occlusion ...

Biosimilar Ranibizumab Effective in Treating RVO in a Real-World Setting  The Center for Biosimilars

In India, Razumab, manufactured by Intas Pharmaceuticals, was approved as a similar biologic to ranibizumab in 2015; the retrospective study RE-ENACT ...

Blue Light Damages Retinal Cells in Lab Study  Medscape

A cell-based experiment shows how blue light can damage retinal cells, but it's unclear whether the results translate to humans or if blue light exposure from ...

Branch retinal vein occlusion (BRVO) recovery: Causes, symptoms, and treatment  Bel Marra Health

Branch retinal vein occlusion or BRVO is often referred to as an “eye stroke” and can impact a person's ability to see. The degree of vision loss varies in each ...

Regeneron Pharmaceuticals (REGN) Receives Hold Rating from Canaccord Genuity  Rockland Register

Regeneron Pharmaceuticals (NASDAQ:REGN)'s stock had its “hold” rating reiterated by research analysts at Canaccord Genuity in a report issued on ...

Global Retinal Vein Occlusion Therapeutics Market 2019 Professional Survey Report Forecast To 2024  The Norman Gazette

Global Retinal Vein Occlusion Therapeutics Market gives valuable reviews and key research including the conventional market patterns, forthcoming and ...

Allergan Receives Approval for Ozurdex® (Dexamethasone Intravitreal Implant 0.7 mg) in China for the Treatment of Retinal Vein Occlusion (RVO)  PR Newswire

DUBLIN, Oct. 30, 2017 /PRNewswire/ -- Allergan plc (NYSE: AGN) announced today that it has received an Imported Drugs License (IDL) from the Chinese Food ...

Aflibercept Injections Superior to Laser for Macular Edema  Medscape

Intravitreal injections of aflibercept were more effective than laser therapy for the treatment of macular edema secondary to branch retinal vein occlusion, ...

UBS Group Trims Regeneron Pharmaceuticals (REGN) Target Price to $440.00  Rockland Register

Regeneron Pharmaceuticals (NASDAQ:REGN) had its target price trimmed by UBS Group from $480.00 to $440.00 in a research note published on Wednesday ...

VEGF Inhibition Improves Visual Acuity in Macular Edema  Medscape

Ranibizumab improved visual acuity at 6 months in patients with macular edema secondary to ischemic branch retinal vein occlusion, whether or not they ...

Topical Squalamine 0.2% and Intravitreal Ranibizumab 0.5 mg as Combination Therapy for Macular Edema Due to Branch and Central Retinal Vein Occlusion: An Open-Label, Randomized Study  Healio

Ophthalmic Surgery, Lasers and Imaging Retina | BACKGROUND AND OBJECTIVE:To evaluate the effects of squalamine (OHR-102; Ohr Pharmaceuticals, ...

Outlook Therapeutics Announces FDA Acceptance of IND for ONS-5010  GlobeNewswire

Enrollment of U.S. patients in the ONS-5010-002 Phase 3 clinical trial expected to be initiated in calendar Q2 2019.

High systolic BP affects your retina and may lead to complete vision loss  Economic Times

Constant fluctuations in the systolic pressure can lead to many major eye complications.

Outlook Therapeutics Submits IND Application for ONS-5010 to the FDA  GlobeNewswire

CRANBURY, N.J., March 01, 2019 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK) (the “Company”) announced today the submission of its ...

Visual Prognosis of Branch Retinal Artery Occlusion  Medscape (subscription)

What is the relationship between initial visual acuity and visual prognosis in patients with branch retinal artery occlusion (BRAO)?

Regeneron Pharmaceuticals (NASDAQ:REGN) Rating Lowered to Sell at ValuEngine  Rockland Register

Regeneron Pharmaceuticals (NASDAQ:REGN) was downgraded by equities researchers at ValuEngine from a “hold” rating to a “sell” rating in a research report ...

Regeneron Pharmaceuticals Inc (REGN) Position Cut by CIBC Asset Management Inc  Mayfield Recorder

CIBC Asset Management Inc lessened its position in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 0.6% in the first quarter, according to the ...

Regeneron Pharmaceuticals (REGN) Given Hold Rating at Cowen  Rockland Register

Regeneron Pharmaceuticals (NASDAQ:REGN)'s stock had its “hold” rating reaffirmed by Cowen in a research report issued on Tuesday, May 7th, ...

ZEISS Launches First Dual-Speed Swept-Source OCT/OCTA at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting  PRNewswire

The ZEISS PLEX Elite 2.0 is a dual-speed Swept-Source Optical Coherence Tomographer that provides expanded visualization options on how diseases are...

Most effective treatment approaches for uveitic macular edema  Science Daily

Injections of corticosteroids directly into the eye are superior to those placed adjacent to the eye for treating uveitic macular edema, one of the leading causes of ...

Genentech Unveils Positive Phase II Results for the First-Ever Eye Implant to Achieve Sustained Delivery of a Biologic Medicine to Treat People With Wet Age-Related Macular Degeneration (AMD)  BioSpace

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced positive, top line results from the Phase II LADDER study ...

Placenta Growth Factor Market Set to Witness Adamant Growth and Forecast 2019-2025  Pr News

The Placenta Growth Factor market report published by Garner Insights, analysis the market overview considering the latest trends, highlighting their latest ...

BidaskClub Lowers Regeneron Pharmaceuticals (REGN) to Strong Sell  Rockland Register

Regeneron Pharmaceuticals (NASDAQ:REGN) was downgraded by equities researchers at BidaskClub from a “sell” rating to a “strong sell” rating in a research ...

Disorganization of Retinal Inner Layers Linked to Visual Acuity Prognoses  MD Magazine

A new study suggests patients with disorganized retinal inner layers see lesser levels of visual acuity improvement after therapy.

Monthly, PRN doses of ranibizumab similarly effective in RVO  Healio

TORONTO — As-needed and monthly ranibizumab dosing regimens yielded similar visual acuity gains in patients with retinal vein occlusion who reached a ...

Steroid Injections May Help Restore Vision In Some Patients With Blocked Eye Veins  Science Daily (press release)

Injecting the eye with the corticosteroid triamcinolone appears effective in improving the vision of some patients with retinal vein occlusion, an important cause of ...

Regeneron's 12-Week Eylea Dose Gets CRL From FDA for Wet AMD  Nasdaq

Regeneron Pharmaceuticals, Inc . REGN suffered a setback when the FDA issued a complete response letter (CRL) to its supplemental Biologics License.

Kodiak Sciences Announces First Quarter 2019 Financial Results and Recent Business Highlights  PRNewswire

PALO ALTO, Calif., May 15, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical-stage biopharmaceutical company specializing in novel ...

Why too much DNA repair can injure tissue: Overactive repair system promotes cell death following DNA damage by certain toxins, study shows  Science Daily

Researchers have discovered how overactive DNA repair systems can lead to retinal damage and blindness in mice. A DNA repair enzyme called Aag ...

FDA OKs Ozurdex for Some With Diabetic Macular Edema  Medscape

The new indication is for treatment of adults with diabetic macular edema who have an artificial lens implant (pseudophakic) or who are scheduled for cataract ...

Branch Retinal Artery Occlusion (BRAO): Causes, Symptoms, Diagnosis, and Treatment  Bel Marra Health

Branch retinal artery occlusion or BRAO is a vision-related disease-causing long-term vision problems. It is caused due to reduced or blocked blood flow.

Regeneron (REGN) to Report Q4 Earnings: Is a Beat in Store?  Nasdaq

Regeneron Pharmaceuticals, Inc . REGN is likely to beat expectations when it releases fourth-quarter and full year 2018 results on Feb 6, before the.

New data comparing Lucentis efficacy and durability versus aflibercept  The Pharma Letter

Swiss pharma giant Novartis (NOVN: VX) today reported new data from a Phase IV head-to-head study (RIVAL) confirming Lucentis (ranibizumab) efficacy and ...

Retina Works Best When Bathed in Vitamin C  Medscape

New research hints at a critical role for ascorbic acid in gamma-aminobutyric acid receptors functioning in the retina, and perhaps the central nervous system.

Regeneron Gains on Eylea, Dupixent and Pipeline Progress  Nasdaq

Shares of Regeneron Pharmaceuticals Inc . REGN have gained 3.2% in the year so far against a decline of 5.9% for the industry . Tarrytown,.

Safety, Tolerability Increases Post-Bevacizumab Injection in Intraocular Pressure  MD Magazine

New research has shown that increased IOP is tolerable to corneal endothelium, and safe for most patients' eyes despite immediate increases post-injection.

Regeneron's sBLA for Eylea Accepted by FDA, Action Date Set  Nasdaq

Regeneron Pharmaceuticals, Inc. REGN announced that the FDA has accepted for review the company's supplemental Biologics License Application (sBLA).

Kodiak Sciences Announces Completion of 12-Week Phase 1a Study of KSI-301 in Patients with Diabetic Macular Edema Demonstrating Safety and Durability of Responses Following Single Dose of Intravitreal Anti-VEGF Antibody Biopolymer Conjugate  PRNewswire

PALO ALTO, Calif., Dec. 21, 2018 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel...

Bayer's Eylea cleared for wider use in Europe  PMLiVE

Bayer's eye disease therapy Eylea has been cleared for a new macular oedema indication in the EU, stepping up competition against rival therapy Lucentis from ...

Eye strokes (retinal artery occlusion): Symptoms, causes, and treatment  Bel Marra Health

Eye strokes can come one suddenly and result in partial or complete loss of vision. Learn about cause, risk factors and treatment options.

Retina Treatment Comparison Data Awaited at EURETINA  Medscape

Results from Navina, HARBOR, and Protocol T, to be presented at the conference, are expected to provide insight into treatments for diabetic macular edema ...

FDA Approves EYLEA® (aflibercept) Injection for Diabetic Retinopathy  PRNewswire

TARRYTOWN, N.Y., May 13, 2019 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug ...

Vision Loss Reported After Cosmetic Facial Injections  Medscape

Dermal filler injections in the forehead led to vision loss, a rare but devastating event, in 3 patients.

Fast Action Can Save Sight if Retina Is Detached or Blocked  New York Times

Modern treatments can do wonders if they are begun before the damage to the eye is irreversible.

News of Note—Japanese robotics company Riverfield bags $10M; Abbott earns CE mark for next-gen stent  FierceBiotech

Japanese robotics player Riverfield scored 1.15 billion yen ($10.1 million) in new financing to fuel its mission to undercut Intuitive Surgical. Nikkei Asian Review ...

Two Ophthalmic Drugs Receive Positive Nods in Europe  Medscape

The European Committee for Medicinal Products has recommended approval of ciclosporin drops for severe keratitis and a new indication for aflibercept.

Ranibizumab Outperforms Aflibercept in Efficacy, Durability  MD Magazine

According to the interim results of the RIVAL trial, ranibizumab (Lucentis) showed an increase of 2.2 more letters compared to aflibercept.

RETINA-AI Releases the First Artificial Intelligence Mobile App for Eye-Care Providers: Fluid Intelligence by RETINA-AI  PR Newswire

HOUSTON, July 17, 2018 /PRNewswire/ -- RETINA-AI has developed and released the first Artificial Intelligence mobile app for eye-care providers. This app ...

Zeiss receives FDA approval for OCT angiography technology  BioOptics World

Zeiss Medical Technology (Dublin, CA) has received FDA clearance for its AngioPlex OCT angiography technology, which enables ophthalmologists to use ...

FDA Clears Ranibizumab for Myopic Choroidal Neovascularization  Medscape

Ranibizumab becomes the first FDA-approved anti-vascular endothelial growth factor therapy for mCNV.

RETINA-AI Releases Android Version of Fluid-Intelligence -- World's First Mobile Artificial Intelligence App for Eye Care Providers  PR Newswire

HOUSTON, Oct. 22, 2018 /PRNewswire/ -- RETINA-AI has released an Android version of its app Fluid-Intelligence, the world's first mobile artificial intelligence ...

Retinal Vein Occlusion Market 2018 Highlights | By Types – Branch Retinal Artery Occlusion, Central Retinal Vein Occlusion | Top 10 Player Analysis by 2023 - Press Release  Digital Journal

Retinal Vein Occlusion Market Information: By Condition (Non-Ischemic and Ischemic), Diagnosis (Optical Coherence Tomography), Treatment and End-User ...

Global Retinal Vein Occlusion Therapeutics Market Study 2019-2025: Sanofi Aventis, Valeant Pharmaceuticals, Allergan  Investor Opinion

The analysis report offers data on Global Retinal Vein Occlusion Therapeutics Market 2018 trends and drivers, revenue, growth, technologies, and on the ...

New Stairway Study Data Shows Potential for Extended Durability with Faricimab in Wet Age-Related Macular Degeneration (AMD)  Business Wire

Faricimab – the first bispecific antibody designed for the eye – dosed every four months demonstrated sustained vision outcomes compared to monthly ...

Pros and Cons of Compounded Pharmaceuticals | Medpage Today  MedPage Today

This article was adapted from a debate that Julia Haller, MD, and Dante Pieramici, MD, presented at the Retina Subspecialty Day prior to the 2016 American ...

Two-year data confirm efficacy of EYLEA® (aflibercept solution for injection) Treat and Extend dosi  PharmiWeb.com

Significant visual acuity gains observed in the first year of treatment with aflibercept were largely maintained for 96 weeks· Up to 60% of patients had an injection ...

Aerie's (AERI) Eye Care Candidate to Enter Clinical Studies  Zacks.com

Aerie's (AERI) Investigational New Drug Application for AR-1105 for the treatment of macular edema due to retinal vein occlusion is accepted by the FDA.

Exposure to High Altitude May Affect Retinal Vessels  Medscape

Retinal vessels may leak at high altitudes, even in healthy adults with no previous history of retinal problems, according to a new study published in the June 5 ...

A Chance Finding of Pigmented Retinal Spots  Medscape

A healthy 6-year-old boy presented to the ophthalmology clinic after being referred for a formal ophthalmologic evaluation of pigmented retinal spots found by an ...

OCT Screening Cost-effective for Diabetic Retinopathy  Medscape

BARCELONA — The use of optical coherence tomography (OCT) to screen everyone with diabetes for retinopathy appears to be a relatively inexpensive way to ...

IRIS Registry Finds New AMD, DME Population Data  MD Magazine

Studies based on data from the world's largest clinical specialty database corrected commonly-perceived trends in ophthalmology.

Regeneron Eylea Hits 24-Week Primary Endpoint in Study  Nasdaq

Regeneron Pharmaceuticals, Inc. REGN announced positive topline results from the phase III study evaluating Eylea (aflibercept) Injection in moderately severe ...

» Load more